Izotropic Reschedules Investor Conference Presentation to March 13th
Izotropic (OTCQB: IZOZF) has announced the rescheduling of its investor conference presentation from February 6th to March 13th, 2025, due to a family emergency affecting the CEO's availability. The presentation will now take place at the OTC's Life Science Virtual Investor Forum.
The company, which specializes in medical device development for breast cancer screening and diagnosis, confirmed that its business plans and progress remain unaffected, with the CEO expected to resume normal business operations next week. One-on-one meetings previously scheduled with the CEO will be rearranged directly with affected parties.
Izotropic (OTCQB: IZOZF) ha annunciato il riprogrammazione della sua presentazione alla conferenza per investitori dal 6 febbraio al 13 marzo 2025, a causa di un'emergenza familiare che influisce sulla disponibilità dell'amministratore delegato. La presentazione si terrà ora al Forum Virtuale per Investitori delle Scienze della Vita dell'OTC.
La società, specializzata nello sviluppo di dispositivi medici per lo screening e la diagnosi del carcinoma mammario, ha confermato che i suoi piani aziendali e i progressi restano inalterati, con l'amministratore delegato che dovrebbe riprendere le normali operazioni aziendali la prossima settimana. Gli incontri individuali precedentemente programmati con l'amministratore delegato saranno riorganizzati direttamente con le parti interessate.
Izotropic (OTCQB: IZOZF) ha anunciado el reprogramado de su presentación en la conferencia de inversores del 6 de febrero al 13 de marzo de 2025, debido a una emergencia familiar que afecta la disponibilidad del CEO. La presentación ahora tendrá lugar en el Foro Virtual de Inversores de Ciencias de la Vida del OTC.
La empresa, que se especializa en el desarrollo de dispositivos médicos para la detección y diagnóstico del cáncer de mama, confirmó que sus planes comerciales y su progreso permanecen inalterados, y se espera que el CEO retome las operaciones comerciales normales la próxima semana. Las reuniones uno a uno que estaban programadas previamente con el CEO serán reprogramadas directamente con las partes afectadas.
아이조트로픽 (OTCQB: IZOZF)는 CEO의 가용성에 영향을 주는 가족 긴급사항으로 인해 투자자 회의 발표를 2월 6일에서 2025년 3월 13일로 재조정했다고 발표했습니다. 발표는 이제 OTC의 생명과학 가상 투자자 포럼에서 진행될 예정입니다.
유방암 선별 및 진단을 위한 의료기기 개발을 전문으로 하는 이 회사는 사업 계획과 진행 상황이 영향을 받지 않았으며, CEO는 다음 주에 정상적인 비즈니스 운영을 재개할 것으로 예상된다고 확인했습니다. CEO와 사전에 예정된 일대일 회의는 관련 당사자들과 직접 재조정될 것입니다.
Izotropic (OTCQB: IZOZF) a annoncé le report de sa présentation lors de la conférence des investisseurs du 6 février au 13 mars 2025, en raison d'une urgence familiale affectant la disponibilité du PDG. La présentation se déroulera désormais lors du Forum Virtuel des Investisseurs en Sciences de la Vie de l'OTC.
La société, spécialisée dans le développement de dispositifs médicaux pour le dépistage et le diagnostic du cancer du sein, a confirmé que ses plans d'affaires et ses progrès demeurent inchangés, le PDG devant reprendre les opérations normales la semaine prochaine. Les réunions individuelles précédemment prévues avec le PDG seront réorganisées directement avec les parties concernées.
Izotropic (OTCQB: IZOZF) hat die Neuterminierung seiner Investorenkonferenzpräsentation vom 6. Februar auf den 13. März 2025 bekannt gegeben, aufgrund eines familiären Notfalls, der die Verfügbarkeit des CEO beeinträchtigt. Die Präsentation wird nun im virtuellen Investorenforum für Lebenswissenschaften des OTC stattfinden.
Das Unternehmen, das sich auf die Entwicklung medizinischer Geräte zur Früherkennung und Diagnose von Brustkrebs spezialisiert hat, bestätigte, dass seine Geschäftspläne und Fortschritte unbeeinträchtigt bleiben, und der CEO voraussichtlich nächste Woche den regulären Geschäftsbetrieb wieder aufnehmen wird. Die zuvor geplanten Einzelgespräche mit dem CEO werden direkt mit den betroffenen Parteien neu terminiert.
- None.
- None.
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 5, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces it is rescheduling its attendance and presentation at the OTC's Virtual Investor Conference from Thursday February 6th to Thursday March 13th, 2025.
Due to a family emergency, the CEO is no longer available to present at the conference as originally scheduled and will instead present at the OTC's Life Science Virtual Investor Forum on March 13th. The Company will announce the registration link when it becomes available.
Those with one-on-one meetings scheduled with the CEO this week will be contacted directly to reschedule, or may do so at the following link: https://calendly.com/izotropic/meeting-with-ceo
The Company's business plans and progress are not affected, and the CEO will resume normal course business next week.
The Company thanks everyone for their understanding.
About Izotropic:
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.
Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.
Contacts:
Izotropic Corporation
Telephone: 1-604-825-4778 or 1-800-IZOCORP ext. 1
Email: info@izocorp.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239854
FAQ
When is Izotropic's (IZOZF) rescheduled investor conference presentation?
Why did Izotropic (IZOZF) reschedule their February 2025 investor presentation?
Will Izotropic's (IZOZF) business operations be affected by the conference rescheduling?
How can investors reschedule their one-on-one meetings with Izotropic's (IZOZF) CEO?
